These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20356946)

  • 1. Prostate cancer incidence rates have started to decrease in central Italy.
    Crocetti E; Ciatto S; Buzzoni C; Zappa M
    J Med Screen; 2010; 17(1):50-1. PubMed ID: 20356946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of screening on prostate cancer rates and trends.
    Mettlin C
    Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
    Stephenson RA; Smart CR; Mineau GP; James BC; Janerich DT; Dibble RL
    Cancer; 1996 Apr; 77(7):1342-8. PubMed ID: 8608513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
    Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
    J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
    Tonita JM; Skarsgard D; Muhajarine N
    Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostatic cancer in the Grand Duchy of Luxembourg. Role of PSA].
    Lamy S; Hein T; Wilmart JF; Capesius C; Scheiden R; Gilson G; Humbel RL
    Bull Soc Sci Med Grand Duche Luxemb; 1998; 135(1):11-23. PubMed ID: 9868829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
    Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
    BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing.
    Okihara K; Nakanishi H; Nakamura T; Mizutani Y; Kawauchi A; Miki T
    Int J Urol; 2005 Jul; 12(7):662-7. PubMed ID: 16045559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
    Ohi M; Ito K; Yamamoto T; Miyakubo M; Takechi H; Kubota Y; Suzuki K
    Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer incidence and survival in relation to education (United States).
    Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M
    Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in prostate cancer incidence and mortality in Germany - effects of opportunistic PSA screening or more?
    Rohde V; Weidner W; Katalinic A
    Urol Int; 2009; 83(2):134-40. PubMed ID: 19752605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.
    Jones JS; Follis HW; Johnson JR
    Prostate Cancer Prostatic Dis; 2009; 12(1):57-60. PubMed ID: 18379587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prostate-specific antigen and hormone levels among men in Singapore and the United States.
    Cheng I; Yu MC; Koh WP; Pike MC; Kolonel LN; Henderson BE; Stram DO
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1692-6. PubMed ID: 16030103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening.
    Gilliland F; Becker TM; Smith A; Key CR; Samet JM
    Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):105-11. PubMed ID: 8049631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.